Sentinel lymph node biopsy in high-risk endometrial cancer: performance, outcomes, and future avenues

Obstet Gynecol Sci. 2022 Sep;65(5):395-405. doi: 10.5468/ogs.22146. Epub 2022 Aug 2.

Abstract

Endometrial cancer is the second most common gynecological malignancy worldwide, with an overall favorable prognosis. However, a subgroup of patients has a high risk of recurrence and poor prognosis. This review summarizes recently published articles that examined sentinel lymph node (SLN) biopsy in patients with high-risk endometrial cancer. We focused on the performance and outcomes of SLN biopsy, and examined potential methods for improving the management of this high-risk subset. Few studies have examined the long-term outcomes of SLN in patients with high-risk endometrial cancer. Thus, we reviewed recently published retrospective studies that have adopted statistical techniques, such as inverse probability weighting or propensity score matching, to examine the outcome of SLN biopsy compared to conventional lymphadenectomy. Potential avenues for future research to fine-tune decision making for this patient subgroup were also discussed.

Keywords: Endometrial cancer; Sentinel lymph node biopsy.